Advertisement
 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
HIV Drug Resistance In Naive Patients
Here's a taste of what TheBody.com has to offer on this topic:
Ask the Experts
Resistance in Long-Term Treatment Naive PatientsI recently tested positive for HIV, but I know for sure that the infection took place in 1993. My doctor said it is highly unusual for someone to go that long having HIV without getting sick (I am sick now, and have been for about 2 months). I am...
Response from Renslow Sherer, M.D.
University of Chicago Hospitals
Everyone with HIV infection in the US, and everyone in a setting where 5% or more of untreated patients have been shown to have acquired a strain of HIV with one or more drug resistance mutations, should have a resistance test before ART is...
Read more »
epivir and drug resistance tests unreliable for naive docsyrs. ago i had a doctor who gave me a pheno-geno type test to see what drugs i was resistant to.... Read more »epivir and drug resistance tests unreliable for naive docsyrs. ago i had a doctor who gave me a pheno-geno type test to see what drugs i was resistant to.... Read more »
Articles
Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D.Listen (1.9MB MP3, 4.5 min.) Daniel Kuritzkes, M.D., is the director of AIDS Research at Brigham and Women's Hospital in Boston, Mass., and an associate professor of medicine at Harvard Medical School. He presented a study at CROI 2007... Read more »
HIV/AIDS Update: Isentress (Raltegravir) Indication Extended for the Treatment of HIV-1 Infection in Treatment-Naive PatientsOn July 8, 2009, FDA granted approval to Isentress (raltegravir), for the treatment of HIV-1 infection in treatment-naive patients. The recommended dose for treatment-naive adult patients is Isentress 400 mg twice daily, with or without food. The... Read more »
Approval of Edurant (Rilpivirine), a New NNRTI, for the Treatment of HIV in Treatment-Naive PatientsOn Friday, May 20, 2011, FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Rilpivirine is an antiviral drug that helps to block reverse transcriptase, an enzyme... Read more »
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected PatientsKenilworth, N.J. -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated a Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected... Read more »
Connect With Others
Drug Resistant HIV
Posted by Anonymous
HiI just found out the strain of hiv i have is resistant to possibly a whole class of NRTIs and PIs..any experience with this for any of you? what could the options be for someone in my situation? I am still treatment naive. Read more » New York draws fire over case of drug-resistantHIV
Posted by Anonymous
Nature 433, 788 (24 February 2005)New York draws fire over case of drug-resistant HIV ERIKA CHECK Rare, aggressive form of AIDS used to publicize dangers of unprotected sex. [WASHINGTON] A decision by New York health officials to announce the detection... Read more » Resisting Resistance - A Story
Posted by Survivor, 1 Reply
Personal Perspective: Resisting Resistance By Matt Sharp Spring 2006 In a little over four months I will turn fifty. When I was diagnosed with HIV in 1988 I never dreamed I'd reach forty. I've survived a long battle with HIV, and it has not been... Read more » Prezista - New PI designed for Resistant Virus
Posted by Survivor, 2 Replies
WASHINGTON, June 23 (Reuters) - U.S. health officials on Friday approved the use of a new HIV drug, made by Johnson & Johnson <JNJ.N>, in combination with related therapies to help treat patients who do not first improve with other...
Read more »
Tools
Advertisement Advertisement
Resource Centers
Guides for People With HIV
|
My Health Tracker
Assess Your Risk for HIV
Find Local HIV/AIDS Services
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
